# Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

> **NCT00633750** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **GENETIC:** TUNEL assay
- **GENETIC:** protein expression analysis
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** liquid chromatography
- **OTHER:** mass spectrometry
- **OTHER:** matrix-assisted laser desorption ionization mass spectrometry
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00633750
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633750, "Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00633750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*